Literature DB >> 8623976

Comparative electrophysiologic and hemodynamic effects of several amide local anesthetic drugs in anesthetized dogs.

P Bruelle1, J Y LeFrant, J E de La Coussaye, P A Peray, G Desch, A Sassine, J J Eledjam.   

Abstract

Large and equipotent doses of several local anesthetics were administered in a cardiac electrophysiologic model on closed-chest dogs. Five groups of pentobarbital-anesthetized dogs were each given intravenously 16 mg/kg lidocaine, 12 mg/kg mepivacaine, 4 mg/kg or 8 mg/kg etidocaine, and 4 mg/kg bupivacaine. Lidocaine induced bradycardia, slowing of atrioventricular node conduction (AH), and marked hemodynamic depression, represented by a decrease in mean aortic pressure (MAoP), in the peak of first derivative of left ventricular pressure (LVdP/dt(max)) and by an increase in left ventricular end-diastolic pressure (LVEDP). Atrial pacing at pacing cycle length (PCL) of 298 ms did not enhance the alteration of variables of ventricular conduction (His ventricle [HV] interval and QRS duration). Mepivacaine induced slight alteration of electrophysiologic variables. Atrial pacing at PCL of 312 ms did not enhance the alteration of HV and QRS duration. Mepivacaine induced transient hemodynamic depression. Etidocaine (4 mg/kg) induced electrophysiologic and hemodynamic alterations similar to mepivacaine but artrial pacing at PCL of 330 ms enhanced HV lengthening and QRS widening (P < 0.05). Etidocaine (8 mg/kg) induced marked impairment of PR, HV, QRS, and QT, and dramatic hemodynamic depression represented by a decrease in MAoP from 123.5 +/- 16.2 at baseline to 36.5 +/- 8.3 mm Hg at 1 min (P < 0.001) and of LVdP/dtmax) from 1446 +/- 379 to 333 +/- 93 mm Hg/s (P < 0.001). Bupivacaine induced dramatic impairment of electrophysiologic variables. Bupivacaine also decreased LVDP/dtmax (from 1333 +/- 347 to 617 +/- 299,P < 0.001) and increased LVEDP. We conclude that mepivacaine induced moderate cardiotoxicity. In contrast, lidocaine induced dramatic hemodynamic depression while etidocaine and bupivacaine markedly impaired both electrophysiologic and hemodynamic variables. This double impairment could explain the great difficulty in resuscitating patients who have had cardiotoxic accidents induced by etidocaine or bupivacaine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623976     DOI: 10.1097/00000539-199603000-00038

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

Review 1.  Anaesthetic agents for advanced regional anaesthesia: a North American perspective.

Authors:  Chester C Buckenmaier; Lisa L Bleckner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Assessment of postoperative analgesia after application of ultrasound-guided regional anesthesia for surgery in a swine femoral fracture model.

Authors:  Joseph M Royal; Timothy L Settle; Michael Bodo; Eric Lombardini; Michael L Kent; Justin Upp; Stephen W Rothwell
Journal:  J Am Assoc Lab Anim Sci       Date:  2013       Impact factor: 1.232

4.  Lipid emulsion for local anesthetic systemic toxicity.

Authors:  Sarah Ciechanowicz; Vinod Patil
Journal:  Anesthesiol Res Pract       Date:  2011-09-29

Review 5.  An extended release local anaesthetic: potential for future use in veterinary surgical patients?

Authors:  B Duncan X Lascelles; Kristin Kirkby Shaw
Journal:  Vet Med Sci       Date:  2016-08-23

6.  Linoleic Acid Attenuates the Toxic Dose of Bupivacaine-Mediated Reduction of Vasodilation Evoked by the Activation of Adenosine Triphosphate-Sensitive Potassium Channels.

Authors:  Soo Hee Lee; Dawon Kang; Seong-Ho Ok; Seong-Chun Kwon; Hyun-Jin Kim; Eun-Jin Kim; Jeong-Min Hong; Ji-Yoon Kim; Sung Il Bae; Seungmin An; Ju-Tae Sohn
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.